Michael Weening - 12 Feb 2026 Form 4 Insider Report for CALIX, INC ((CALX))

Role: President & CEO, Director
Signature: /s/ Tom Gemetti as Attorney-in-Fact for Michael Weening
Issuer symbol: (CALX)
Transactions as of: 12 Feb 2026
Net transactions value: +$19,896
Form type: 4
Filing time: 17 Feb 2026, 16:05:32 UTC
Previous filing: 03 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Weening Michael	President & CEO, Director	C/O CALIX, INC., 3155 OLSEN DRIVE, SUITE 450, SAN JOSE	/s/ Tom Gemetti as Attorney-in-Fact for Michael Weening	17 Feb 2026	0001678385

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	(CALX)	Common Stock	Award	$19,896	+439	+2.7%	$45.32	16,556	14 Feb 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	(CALX)	Stock Option (right to buy)	Award	$0	+217,500		$0.000000	217,500	12 Feb 2026	Common Stock	217,500	$39.68	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Calix, Inc. Amended and Restated Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 15, 2025 through February 14, 2026. This transaction is exempt under Rule 16b-3(c).
F2	In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 13, 2026, the last trading day of the purchase period.
F3	On January 31, 2025, the reporting person was granted a performance-based option to purchase 217,500 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.